Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 33 - Antiparasitic agents
Patents for A61P 33 - Antiparasitic agents (21,787)
05/2003
05/07/2003EP1307443A2 Novel substituted diaryl azepine derivatives as integrin ligands
05/07/2003EP1307204A1 Protease inhibitors
05/07/2003EP1307203A1 Protease inhibitors
05/07/2003EP1140825B1 Melatonin derivatives and medicine containing same
05/07/2003EP1112251B1 Azetidine derivatives, preparation and medicines containing them
05/07/2003CN1416428A Compounds having antitumor activity: process for their prepn.and pharmaceutical compsns. contg. them
05/07/2003CN1416421A New CCRS modulators: benzimidazoles or benzotriazoles
05/07/2003CN1416354A Vascular endothelial growth factor 2
05/07/2003CN1416346A Peotease inhibitors
05/07/2003CN1416339A IL-8 receptor antagonsts
05/07/2003CN1415371A Medicament for curing colpitis mycotica and trichomonal vaginitis and its preparation method
05/07/2003CN1107501C Albendazole emulsion
05/06/2003US6559280 Controlling protein levels in eucaryotic organisms
05/06/2003CA2031811C Toxoplasma gondii antigens, the preparation thereof and the use thereof
05/02/2003EP1306084A1 Compositions for the control of parasitic infestations in fish
05/02/2003EP1305031A2 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents
05/02/2003EP1105381B1 Dibenzothiophene compounds and methods of use thereof
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035696A2 Humanized antibodies against icam-1, their production and uses
05/01/2003WO2003035651A2 Novel artemisinine derivatives, and uses thereof for treating malaria
05/01/2003WO2003035643A1 Pyrazolyl-substituted heterocycles and their use as phytosanitary products
05/01/2003WO2003035102A1 Use of egf to inhibit pathogenic infections of the urogenital tract
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035029A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/01/2003WO2003035012A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003WO2003034825A1 Anthelmintic composition
05/01/2003WO2002049633A3 Use of amidoamines to treat or prevent acanthamoeba and fungal infections
05/01/2003WO2002049627A3 Antifungal compositions containing an antibiotic and one or more amidoamines
05/01/2003WO2002038600A3 C. elegans genes involved in viability and/or reproduction and uses thereof
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082107 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
05/01/2003CA2793019A1 Humanized antibodies
05/01/2003CA2464609A1 Use of egf to inhibit pathogenic infections of the urogenital tract
05/01/2003CA2464403A1 Anthelmintic composition
05/01/2003CA2464349A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003CA2454361A1 Humanized antibodies
04/2003
04/30/2003CN1414847A Sustained-releasing antihelmintic compositions comprising praziquantel
04/30/2003CN1414102A Binding region of erythrocyte binding protein of Plasmodium vivax and Plasmodium falciform
04/30/2003CN1414018A Binding region of erythrocyte binding protein of plasmodium vivax and plasmodium falciform
04/30/2003CN1413611A Natural oral preparation for prevention and curing acne and brandy nose
04/30/2003CN1107072C Programing cell death induced molecule II
04/29/2003US6555569 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
04/29/2003US6555524 Ketolide antibiotics
04/29/2003US6555523 Use of cirsiliol and derivatives to treat infections
04/25/2003CA2409910A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
04/24/2003WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033031A1 Dosage form, device and methods of treatment
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032928A2 Therapeutic composition and use
04/24/2003WO2003032911A2 Anti-angiogenic and cytotoxic fused pyrimidines
04/24/2003WO2003032905A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity
04/24/2003WO2002098850A3 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
04/24/2003WO2002049576A9 Fab i and inhibition of apicomplexan parasites
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003US20030078541 Device for injection of antiparasitic agents in pets
04/24/2003US20030078417 For protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents; for therapy of phospholipase mediated injury, injury due to oxidation, and inflammation
04/24/2003US20030078398 Recombinant DNA molecules encoding aminopeptidase enzymes and their use in the preparation of vaccines against helminth infections
04/24/2003US20030078390 Tissue cement proteins from Rhipicephalus appendiculatus
04/24/2003US20030078299 Anti-cancer nitro- and thia-fatty acids
04/24/2003US20030078291 Novel compound having antimalarial activity
04/24/2003US20030077802 Human PRL1 phosphatase
04/24/2003US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor
04/24/2003US20030077247 Chemokines as adjuvants of immune response
04/24/2003US20030077228 Polar solvent 30-99.69%, active compound 0.001-60%, and f lavoring agent 0.1-10%; propellant free
04/24/2003US20030077227 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
04/24/2003CA2722197A1 Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
04/24/2003CA2684419A1 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity
04/24/2003CA2463991A1 Therapeutic composition and use
04/24/2003CA2463674A1 Controlled release capsules for providing both pulsed burst and controlled release of drugs to the rumen of ruminant animals over an extended time period
04/23/2003EP1303503A2 Aniline derivatives
04/23/2003EP1303500A1 Heterocyclic fluoroalkenyl thioethers (ii)
04/23/2003EP1303300A1 Compositions and methods for treatment of candidiasis
04/23/2003EP1303263A2 Antibacterial method and composition wth phenolic compounds
04/23/2003EP1027359B1 Monocyclic l-nucleosides, analogs and uses thereof
04/23/2003EP1003764B1 Improved process for preparing antiparasitic agent
04/23/2003CN1413216A Azolyalkyl-oxa (di) azolyl pyri (mi) dine derivatives, method for their production and use as pesticides
04/23/2003CN1413193A Nitrile derivatives as cathepsin K inhibitors
04/23/2003CN1106386C Parasiticidal pyrazole compound
04/22/2003US6552183 Moncyclic L-nucleosides analogs
04/22/2003US6552010 Treatment of SLE with dehydroepiandrosterone
04/22/2003US6552002 Miticides, parasiticides; veterinary medicine
04/22/2003US6551594 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
04/22/2003US6551586 Merozoite surface antigen1 (MSA1); vaccinia virus expression vector which expresses a malaria MSA1 peptide in combination with a signal peptide and anchor peptide in a host animal
04/17/2003WO2003031939A2 Protein modification and maintenance molecules
04/17/2003WO2003031599A2 Live attenuated salmonella strains for producing vaccines
04/17/2003WO2003031458A1 Methods for synthesis of diarylmethanes
04/17/2003WO2003031394A1 Organic compounds
04/17/2003WO2003031393A2 Carbonyloxy-cyanomethyl compounds as antiparasitic agents
1 ... 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 ... 218